Amylyx Pharmaceuticals, Inc. (AMLX) /
The cash flow of Amylyx Pharmaceuticals, Inc. over the past 5 years
Chart Amylyx Pharmaceuticals, Inc.: operating cash flow, capital expenditures, free cash flow, fiscal 2021–2025 Open the chart →In fiscal 2025, the latest fiscal year on file, Amylyx Pharmaceuticals, Inc.'s operating cash flow was -$123.34M and its capital expenditures $138K, leaving free cash flow of -$123.48M. Free cash flow was above zero in 1 of the 5 years shown. It ranged from -$182.4M in fiscal 2022 to $10.68M in fiscal 2023. Capital expenditures were highest in fiscal 2022, at $2.53M.
Year by year
| Fiscal year | Operating cash flow | Capital expenditures | Free cash flow* |
|---|---|---|---|
| 2025ended Dec 31, 2025 | -$123.34M | $138K | -$123.48M |
| 2024ended Dec 31, 2024 | -$167.65M | $157K | -$167.8M |
| 2023ended Dec 31, 2023 | $11.92M | $1.24M | $10.68M |
| 2022ended Dec 31, 2022 | -$179.87M | $2.53M | -$182.4M |
| 2021ended Dec 31, 2021 | -$74.8M | $353K | -$75.15M |
Fiscal years as Amylyx Pharmaceuticals, Inc. reports them. * Calculated by us from the company's filed figures; — no figure on file. From SEC filings, updated nightly. How each line is read.
More on Amylyx Pharmaceuticals, Inc.
- The revenue of Amylyx Pharmaceuticals, Inc.
- The profitability of Amylyx Pharmaceuticals, Inc.
- The debt of Amylyx Pharmaceuticals, Inc.
- All of Amylyx Pharmaceuticals, Inc.'s financials, charted
Companies of a similar size
- CLBTCellebrite DI Ltd.
- IMAXIMAX Corporation
- KNFKnife River Corporation
- AVAHAveanna Healthcare Holdings Inc.
- EEFTEURONET WORLDWIDE, INC.
Not investment advice. This page shows what Amylyx Pharmaceuticals, Inc. filed with the SEC. Nothing here is a recommendation about any security. Check important figures against the company's own filings.